(Q40109446)

17 September 2017

The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model (English)

1 reference

17 September 2017

0 references

1 reference

2

Stephen S Whitehead

1 reference

17 September 2017

14

Anna P Durbin

1 reference

17 September 2017

9

Kawsar R Talaat

1 reference

17 September 2017

Beth D Kirkpatrick

1

1 reference

17 September 2017

Kristen K Pierce

3

1 reference

17 September 2017

Cecilia M Tibery

4

1 reference

17 September 2017

Palmtama L Grier

5

1 reference

17 September 2017

Noreen A Hynes

6

1 reference

17 September 2017

Catherine J Larsson

7

1 reference

17 September 2017

Beulah P Sabundayo

8

1 reference

17 September 2017

Anna Janiak

10

1 reference

17 September 2017

Marya P Carmolli

11

1 reference

17 September 2017

Catherine J Luke

12

1 reference

17 September 2017

Sean A Diehl

13

1 reference

17 September 2017

language of work or name

English

0 references

publication date

16 March 2016

1 reference

Science Translational Medicine

17 September 2017

1 reference

17 September 2017

8

1 reference

17 September 2017

330

1 reference

17 September 2017

330ra36

1 reference

The global distribution and burden of dengue

17 September 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Antibodies determine virulence in dengue

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Neutralization and antibody-dependent enhancement of dengue viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Efficacy of a tetravalent dengue vaccine in children in Latin America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Correlates of protection induced by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Immune correlates for dengue vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Dengue human infection models to advance dengue vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Underrecognized mildly symptomatic viremic dengue virus infections in rural Thai schools and villages

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Asymptomatic humans transmit dengue virus to mosquitoes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Experimental human challenge infections can accelerate clinical malaria vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.AAF1517

Research on dengue during World War II

21 January 2018

1 reference

21 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.4269/AJTMH.1952.1.30

Identifiers

DOI

10.1126/SCITRANSLMED.AAF1517

1 reference

17 September 2017

1 reference